Purdue Pharma: Innovative Healthcare Solutions

Eisai and Purdue Pharma Announce Buy Out of Purdue’s Rights in Worldwide Collaboration to
Develop and Commercialize Lemborexant

Apr 30, 2019

WOODCLIFF LAKE, N.J. and STAMFORD, Conn. – April 30, 2019 – Eisai Inc. and Purdue Pharma L.P. today announced ... Read more

FDA Grants Competitive Generic Therapy (CGT) Designation to Purdue Pharma’s Investigational Nalmefene
HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose

Apr 24, 2019

Committed to advancing solutions to the opioid addiction crisis, Purdue will not profit from nalmefene HCl Stamford, Conn. ... Read more

Purdue Pharma Announces Landmark Agreement with Oklahoma
to Advance the Treatment of Addiction

Mar 26, 2019

Settlement will establish national center for addiction studies and treatment in Tulsa; Sackler family announces voluntary contribution to ... Read more

FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the
Emergency Treatment of Known or Suspected Opioid Overdose

Mar 13, 2019

Committed to advancing solutions to the opioid public health crisis, Purdue will not profit from nalmefene HCl STAMFORD, ... Read more

Purdue Pharma Statement to 60 Minutes Regarding the Segment on Opioid Medicines
Expected to Air Sunday, February 24, 2019

Feb 22, 2019

In 1995, the U.S. Food and Drug Administration (FDA) approved OxyContin® (oxycodone HCI) extended-release tablets CII (current Full ... Read more

Patients Who Receive Information About the Importance of Safe Disposal are Three Times More Likely to Dispose of Unused Prescription Opioid Medications

Feb 20, 2019

Survey study sponsored by Purdue Pharma and published in the Journal of Pain Research examines factors that contribute ... Read more

More news

Recent News